JPRN-jRCT2080222787未知3 期
Confirmatory Study for AD-810N in Patients with Parkinsonism in Dementia with Lewy Bodies.(Phase 3 study)
试验速览
- 阶段
- 3 期
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 89age old（—）
- 性别
- All
入选标准
- •Patients met the diagnostic criteria of probable DLB
- •- Outpatients
- •- Patients taking L-DOPA/DCI in succession more than 12 weeks
排除标准
- •- Patients with parkinsonism excepting Dementia with Lewy Bodies
- •- Patients with Parkinson's disease with dementia
- •- Epileptic patients
- •- Patients treated with zonisamide
研究者
相似试验
未知
2 期
An Exploratory Study for AD-810N in Patients with Parkinsonism in Dementia with Lewy Bodies (Phase 2 study)JPRN-jRCT2080221994Dainippon Sumitomo Pharma Co., Ltd.150
未知
3 期
A double-blind confirmatory study for AD-810N (zonisamide) in patients with Parkinson's disease (Phase III)Parkinson's diseaseJPRN-jRCT2080221162Dainippon Sumitomo Pharma Co., Ltd.360
进行中（未招募）
1 期
A Phase 1 trial of pf-03084014 in patients with advanced solid tumor malignancy and t-cell acute lymphoblastic leukemia/lymphoblastic lymphoma - NDadvanced solid tumor malignancies or relapsed or refractory acute T-cell lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL).MedDRA version: 9.1Level: LLTClassification code 10066110MedDRA version: 9.1Level: LLTClassification code 10065252MedDRA version: 9.1Level: LLTClassification code 10065923EUCTR2010-022036-36-ITPfizer Inc., 235 East 42nd Street, New York, NY 1001760
终止
2 期
Cemdisiran and eculizumab dose-ranging study for paroxysmal nocturnal haemoglobinuriaParoxysmal nocturnal haemoglobinuria (PNH)Haematological DisordersParoxysmal nocturnal haemoglobinuria [Marchiafava-Micheli]ISRCTN31882639niversity of Leeds9
进行中（未招募）
1 期
A study that continues from APD334-003 which investigates the safety and effectiveness of treatment with the drug APD334 in patients with ulcerative colitis (a form of inflammatory bowel disease)EUCTR2015-002109-12-BGArena Pharmaceuticals, Inc.118